12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bronchitol mannitol regulatory update

Pharmaxis voluntarily withdrew a marketing application in Australia for Bronchitol to treat bronchiectasis. The company said that the quality of life co-primary endpoint used in...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >